Boston-based Dana-Farber Cancer Institute (DFCI) entered into a collaborative agreement with an Australian oncology-focused biotech called Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) to investigate a drug called paxalisib (formerly GDC-0084) targeting primary central nervous system (CNS) lymphoma, a potential new indication for this drug. The study will be led by Dr. Lakshmi Nayak, Director of CNS Lymphoma Center at DFCI.
Lymphoma is a cancer of white blood cells. It occurs in the lymphatic system and can spread across the body. Primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system. Presently, the existing P13K inhibitors approved by the U.S. Food and Drug Administration (FDA) treat forms of lymphoma, however, they are deemed ineffective for PCNSL, since they cannot cross the blood-brain barrier. Now DCCI initiates an open-label Phase 2 clinical trial of paxalisib in PCNSL.
PCNSL accounts for about 4% of brain tumors, but the incidence is growing with time. Patients are often in their 60s or older and are more common among men. The primary treatment includes chemotherapy and radiotherapy, but recurrence is common and on...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).